Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Associated Therapies: -

Clinical Trials

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

First Posted Date: 2015-01-28

Last Posted Date: 2024-06-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 307

Registration Number: NCT02348216

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of California Los Angeles (UCLA), Santa Monica, California, United States
🇨🇦
Princess Margaret, Toronto, Ontario, Canada

and more 33 locations

Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

Phase 2

Completed

Conditions: Chronic Lymphocytic Leucemia

Interventions: Drug: Bendamustine
Drug: GA101
Drug: Ibrutinib

First Posted Date: 2015-01-26

Last Posted Date: 2019-05-08

Lead Sponsor: German CLL Study Group

Target Recruit Count: 66

Registration Number: NCT02345863

Locations: 🇩🇪
German CLL Study Group, Cologne, Germany

CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients

Phase 2

Conditions: Chronic Lymphocytic Leucemia

Interventions: Biological: GA101 (Obinutuzumab)
Drug: Bendamustine

First Posted Date: 2014-12-19

Last Posted Date: 2018-08-13

Lead Sponsor: Munich Municipal Hospital

Target Recruit Count: 27

Registration Number: NCT02320383

Locations: 🇩🇪
German CLL Study Group, Cologne, Germany

A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Bendamustine
Drug: Obinutuzumab

First Posted Date: 2014-12-19

Last Posted Date: 2020-02-11

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 102

Registration Number: NCT02320487

Locations: 🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸
Cancer Care & Hematology; Specialists of Chicagoland, Niles, Illinois, United States
🇺🇸
San Juan Oncology Associates, Farmington, New Mexico, United States

and more 23 locations

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Phase 1

Withdrawn

Conditions: Plasma Cell Leukemia
Multiple Myeloma

Interventions: Drug: Bendamustine

First Posted Date: 2014-12-11

Last Posted Date: 2024-02-16

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT02315157

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Bendamustine
Drug: Obinutuzumab
Drug: Polatuzumab vedotin (Liquid)
Drug: Polatuzumab vedotin (Lyophilized)
Drug: Rituximab

First Posted Date: 2014-10-06

Last Posted Date: 2022-11-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 331

Registration Number: NCT02257567

Locations: 🇳🇱
UMC St. Radboud; Hematology, Nijmegen, Netherlands
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Swedish Cancer Inst., Seattle, Washington, United States

and more 59 locations